beyond spring pharmaceuticals stock

Shares of the company were trading at their highest level since May 2018. On average they predict BeyondSprings share price to reach 3000 in the next twelve months.

Beyondspring Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution Nasdaq Bysi Seeking Alpha

In China we own a 5797 interest in our Chinese subsidiary Dalian Wanchunbulin Pharmaceuticals Ltd.

. View analysts price targets for BeyondSpring or view top-rated stocks among Wall Street analysts. Open an Account Now. Stock is down 76 over the past year.

The company is forecast to post a net loss per share of US164 next year compared to a net loss per share of US164 last year. All quotes are in local exchange time. The pharmaceutical company focused on the development of cancer therapeutics said on Tuesday it is implementing a 35 reduction in its US.

BeyondSpring NASDAQBYSI Get Rating last. Amgen IncAmgen is a leader in biotechnology-based human therapeutics with historical expertise in renal disease and cancer supportive-care productsFlagship drugs include red. Price target increased to US1367.

Find Out What Services a Dedicated Financial Advisor Offers. That rank is primarily influenced by a long-term technical score of 97. BYSI stock are taking off on Wednesday following an important update regarding the firms lung cancer treatment.

Modernas stock rose 28X in the past 2 years are these biotech picks next. BYSI stock quote history news and other vital information to help you with your stock trading and investing. Learn How to Make Your Saving Goals a Reality.

In other cancer-drug news Infinity Pharmaceuticals. BeyondSpring Pharmaceuticals holds the No. December is off to.

This suggests a possible upside of 19134 from the stocks current price. BeyondSpring has a twelve month low of 113 and a twelve month high of 3300. They possess deep scientific clinical regulatory operational and financial expertise in both the US.

Up from US1175 the current price target is an average from 4 analysts. BeyondSpring Pharmaceuticals Granted US. The pharmaceutical company announced that its.

The stock was up 188 at 2774 as of 132 pm. A thumbs down from the FDA has sent BYSI stock into free fall this morning. Ad Biotech is becoming one of the best new sectors for investing if you know where to look.

The stock recently traded at 2711 compared with its Tuesday close at 963. Patent 11229642 Composition and method for reducing neutropenia Benzinga - Jan 25 2022 532AM BeyondSpring Cuts On-Third Of Its Workforce. Real-time last sale data for US.

Headquartered in New York City we are committed to raising the standard of care for cancer patients with first-in-class treatments that improve lives and clinical outcomes for millions of patients in need. Ad Searching for Financial Security. Our lead asset a first-in-class agent plinabulin is a selective immunomodulating microtubule-binding agent that is being.

2 days agoShares of BYSI opened at 177 on Friday. 129 rank among its peers in the Medical-BiomedBiotech industry group. Ad No Hidden Fees or Minimum Trade Requirements.

Their forecasts range from 500 to 6500. It had slid 27 in the six months through Tuesday. By the close of.

About BeyondSpring Pharmaceuticals Headquartered in New York City BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes. Find the latest BeyondSpring Inc. On 82621 Beyond announced a favorable partnership with Jiangsu Hengrui Pharmaceuticals the leading Chinese oncology drug company to distribute and co-develop Plinabulin in Greater China which.

BeyondSpring is a global clinical-stage bio-pharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with the University of Washington in de novo drug discovery using a. Shares of BeyondSpring NASDAQ. New target price is 462 above last closing price of US243.

2 days agoThe stock has a market capitalization of 6891 million a PE ratio of -108 and a beta of 121. The company on Wednesday said plinabulin its lead drug met the. Wanchunbulin which owns a 100 interest in plinabulin.

Intraday data delayed at least 15 minutes or per exchange. Beyondspring Inc stock is up 3400 over the last 12 months and the average rating from Wall Street analysts is a Strong BuyInvestorsObservers proprietary ranking system gives BYSI stock a score of 82 out of a possible 100. BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulins Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition - Yahoo Finance.

Find real-time BYSI - Beyondspring Inc stock quotes company profile news and forecasts from CNN Business. Stock quotes reflect trades reported through Nasdaq only. And China which ideally positions us to accomplish our near- and long-term objectives.

BYSIs rank also includes a fundamental score of 84. By Samuel OBrient InvestorPlace Financial News Writer Dec 1 2021 1258 pm EST. Our management team is made up of a strong and diverse group whose specialties range from early-phase development to global clinical development.

Workforce which is expected to result in cost savings. Shares of BeyondSpring BYSI 985 soared on Wednesday after the pharmaceutical company released promising clinical trial results for its investigational lung cancer treatment. 1 We own global rights to plinabulin in all countries except China.

The company showed -6 earnings growth last quarter while sales growth came in at 0. The Closing Price Days High Days Low and Days Volume have been adjusted to account for any stock splits andor dividends which may have occurred for this security since the date shown above.

Beyondspring Linkedin